Dorzolamide (hydrochloride)

Dorzolamide (L671152) hydrochloride is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity[1].

Product Specifications

CAS Number

[130693-82-2]

Product Name Alternative

L671152 hydrochloride; MK507 hydrochloride

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Carbonic Anhydrase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Others; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Dorzolamide-hydrochloride.html

Purity

99.86

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 12.5 mg/mL (ultrasonic)

Smiles

O=S(C(S1)=CC2=C1S([C@@H](C)C[C@@H]2NCC)(=O)=O)(N)=O.Cl

Molecular Formula

C10H17ClN2O4S3

Molecular Weight

360.90

Precautions

H302, H315, H319, H335

References & Citations

[1]J Biollaz, et al. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol. 1995;47 (5) :455-60.|[2]Sangly P Srinivas, et al. Inhibition of carbonic anhydrase activity in cultured bovine corneal endothelial cells by dorzolamide. Invest Ophthalmol Vis Sci. 2002 Oct;43 (10) :3273-8.|[3]Belal M Ali, et al. Dorzolamide synergizes the antitumor activity of mitomycin C against Ehrlich's carcinoma grown in mice: role of thioredoxin-interacting protein. Naunyn Schmiedebergs Arch Pharmacol. 2015 Dec;388 (12) :1271-82.